GrowBLOX Sciences, Inc. (GBLX) Cultivation Technology

New Post Public Reply Private Reply Replies (0) Message Board
QualityStocks
GrowBLOX Sciences, Inc. (GBLX) Cultivation Technology Promises to Deliver Pure, High-Value Strains at Scalable Production Volumes

Medical marijuana continues to act as the narrow end of the wedge for a broader legalization of cannabis and cannabis-derived products nationwide, with parents now demanding medical access across the country to what they see as relatively-safe, life-saving drugs. Such as in the cases like those of two young girls in Pittsburgh (where legislation is currently pending that would allow medical marijuana to be used), ages 12 and 15, reported recently by NBC News. One girl is barely able to move after a nasty series of epileptic seizures and the other was just discharged after a similar episode, consisting of 15 grand mal seizures that occurred within a period of 36 hours.

The mothers of both girls are members of a growing army of parents and national marijuana advocates pushing for legislative reform on the cannabis issue. This efflorescing movement, led by medical access and compassionate care concerns, is being spurred on by the mounting body of empirical evidence emerging from landmark clinical studies which are daily helping to document the benefits of phytocannabinoids, such as CBD (cannabidiol, a non-psychoactive cannabinoid) and THC (the more famous psychoactive cannabinoid), for treating conditions like epilepsy, as well as helping to regulate a wide variety of other problematic conditions, such as chronic pain. In this case, one of the girls is actually enrolled in an ongoing clinical trial, while the other is not. This case shines a bright light on the underlying problem of state legislatures dragging their feet on the issue and offers stark contrast for the recent FDA approval of prescription opioid OxyContin for children as young as 11, who are recovering from extensive trauma or major surgery.

On the other end of the cannabis legalization spectrum from compassionate care and medical access forces we have tax revenues, which are extremely appealing to increasingly strapped state legislatures, and which are looking more and more politically feasible given the growing receptivity to marijuana reform among the general populace. Just recently, ResponsibleOhio, a marijuana reform advocacy group with a $20 million war chest, which is pushing hard for the legalization of at least medical marijuana (MMJ) in Ohio, secured enough signatures to get a ballot initiative on the books for this November. County and local government officials are already starting to buzz about the estimated $554 million in annual tax revenues projected by ResponsibleOhio’s newest report if the state’s legal, regulated cannabis market stabilizes by 2020.

With Washington bringing in $70 million in tax revenues and Colorado pulling down around $40 million during their first years, seven other states are currently poised to pass similar reforms that would at least allow MMJ access for patients. In Nevada, where MMJ was technically legalized back in 2000, dispensaries are just now cropping up after the passage of Senate Bill 374 in 2013, and the subsequent dolling out of operating licenses beginning in late November last year. Clark County, where Las Vegas resides, has been the tip of the spear in many respects, passing its own proactive zoning and land use process regulations for MMJ businesses ahead of schedule. A fact not lost on some analysts, who are projecting a rapid flourishing of the state’s cannabis market. With estimates of around $100 million plus in annual revenues, driven in part by a currently still emerging health tourism-centric regulatory structure, as well as the never-ending influx of people from all over the world who flock to the global entertainment mecca that is Las Vegas every year, Nevada could be one of the fastest growing national markets for cannabis, medical or otherwise.

This seemingly ideal market environment is a major reason why plant biology and cultivation focused biopharma, GrowBLOX Sciences (OTC: GBLX), has targeted Nevada for the rollout of its principal cultivation facility, which will be furnished with the company’s proprietary suite of technologies designed to achieve scalable production of consistently top quality MMJ materials and extracts. With initial production-model units of the company’s GrowBLOX™ controlled-environment solution already shipped to its GB Sciences Nevada (GBSN) and GB Sciences Puerto Rico (GBS PR) facilities, GBLX is fast on its way to demonstrating to the now $3.5 billion U.S. market (2015 estimate according to ArcView), just how far the company has come in terms of designing an efficient lifecycle cultivation solution.

GrowBLOX Sciences is looking to become a major player as the cannabis sector swells to around $10.8 billion over the next four years, deploying its solution – which spans tissue culture propagation of high-value proprietary strains in a controlled environment, through to consistently top quality end product and derived extracts – to eager regions which have passed the requisite reforms. Having secured a $1.75 million funding commitment for the build out of its initial MME (medical marijuana establishment) back in June and having subsequently reported in late July that the company is on track to complete the build of its Nevada Cultivation Labs, GBLX has now reached a major transitional milestone, where the company is focused on branding, production, revenue generation and staffing, instead of R&D, or licensure efforts.

Nevada’s 136 licensed dispensaries, combined with a lack of in-state cultivation, makes this a particularly auspicious move by GBLX, and the company’s state-of-the-art cultivation facility should not only impress sector players by its prowess, it should capture a sizeable share of a state market that is currently estimated as growing by around 341 percent this year alone. Pacific Leaf Ventures ponied up the $1.75 million funding commitment for this initial cultivation lab and has also provided license for IP related to its highly recognizable brand names of cannabis, as well as certain cultivation and extraction techniques. Slated to begin producing sometime in Q4 this year, GLBX’s Nevada Cultivation Labs will not only secure the reputation of the Pacific Leaf brand name and the quality of its cannabis strains through impeccably consistent output (fueling the local market with a scalable supply of products), it will also help cement brand identity and recognition among patients with reciprocal MME cards from neighboring states like Arizona and California.

The incredibly powerful TissueBLOX, GrowBLOX and CureBLOX cultivation architecture developed by GBLX, which allows for scalable production of genetically pure strains of cGMP-certified cannabis, has the potential to transform the cultivation segment of the burgeoning nationwide cannabis space.

Investors are encouraged to learn more about the technology by visiting www.growblox.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

GB Sciences, Inc. (GBLX) Stock Research Links

GBLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 47

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 100

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 0

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 226

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 109

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 16

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
RCA Mount Dora Widens Addiction Care Insurance Reach

Updated Category News Views 44

Insurance paperwork rarely looks heroic, yet it can decide whether treatment starts before a crisis gets worse. Recovery Centers of America at Mount Dora has added Aetna and Cigna/Evernorth to its in-network roster for every level of substance use disorder care, a practical move with real consequences for patients and families across Central Florida. Coverage matters most...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 88

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

T-Mobile US: A Decade of Impressive Stock Growth Revealed

Updated Category News Views 142

T-Mobile US and Its Remarkable Growth Journey T-Mobile US (NASDAQ: TMUS) has shown exceptional growth over the last decade. With an annualized return rate of 20.05%, the company has outpaced the broader market by 8.22%. As of the latest information available, T-Mobile's market capitalization stands at an impressive $269.40 billion, highlighting its substantial position...

Continue Reading
Analysts Adjust TFI International's Forecasts After Q3 Report

Updated Category News Views 67

TFI International Reports Weaker-Than-Expected Q3 Earnings After the market closed on a recent Monday, TFI International (NYSE: TFII) announced its quarterly earnings figures, which unfortunately fell below expectations. The company reported earnings of $1.60 per share, compared to analyst predictions of $1.78 per share. In addition, TFI International's quarterly revenue...

Continue Reading
C3.ai Investors Face Class Action Amidst Poor Financial Results

Updated Category News Views 179

C3.ai Class Action Overview The Portnoy Law Firm is stepping forward to represent investors of C3.ai, Inc. as a class action develops. This legal move comes after concerning preliminary financial results announced by the company. Investors who purchased securities of C3 during the specified class period are encouraged to engage with the firm. Details of the Legal Class...

Continue Reading
21st.BIO Seeks EU Nod for Precision Fermentation Tech

Updated Category News Views 172

Is Precision Fermentation Europe's Next Big Bet? Here we go again with another tech trying to revolutionize the food industry, and this time it's the Danish company 21st.BIO making strides in Europe. They've tossed their hat in the ring with an EU Novel Food application for BLG Essential+™, hoping to weave precision fermentation into the fabric of European food...

Continue Reading
Key Pfizer Executives Support Current Leadership Amid Challenges

Updated Category News Views 105

Support for Pfizer's Leadership from Former Executives In a recent statement, former Pfizer executives, Ian Read and Frank D'Amelio, clarified their stance regarding the ongoing campaign by activist investor Starboard Value. They emphasized that they will not be engaging with Starboard, which has been advocating for changes within the pharmaceutical giant to enhance its...

Continue Reading